Applied Nutrition plc (LSE:APN) - The Merseyside-based sports nutrition group has twice lifted its full-year Revenue guidance and bought a US Manufacturing plant, as it pushes deeper into North America barely 18 months after floating in London.

Applied Nutrition, the Liverpool-headquartered maker of protein powders, pre-workout supplements and functional drinks, has spent 2026 confounding the sceptics who greeted its stock-market debut. A company that priced its initial public offering at the lower end of its range in late 2024 has since become one of the London market's more striking consumer growth stories, with the shares changing hands well above their listing price.

The catalyst has been a run of upgrades. Having guided the market towards roughly £140m of revenue for the year to 31 July 2026, management lifted that figure again in the summer to around £148m, and simultaneously announced the Acquisition of a US manufacturing Facility designed to underpin its ambitions across the Atlantic.

For a Business whose international sales already account for more than half the group total, the message to investors has been consistent: Demand is running ahead of expectations, and the infrastructure is now being put in place to meet it.

Latest Development

In early June, Applied Nutrition announced it had agreed to acquire the trade and majority of the Assets of Nutrablend Group, a US contract manufacturer, for around $16m (approximately £12m). The deal brings a freehold, six-acre site in Buffalo, New York, comprising roughly 107,000 sq ft of office, Warehouse and production space, together with five powder-filling lines, three stick-pack machines and other equipment. The company said the facility has annual production capacity of up to $300m and will serve the US, Canadian and Latin American markets.

The acquisition also delivered two consumer brands, Basic Supplements and GR8 Lifestyle, and roughly 100 staff, including the existing management team. Alongside the deal, Applied Nutrition disclosed a new North American collaboration with Mondelez International to produce sports nutrition products under the SOUR PATCH KIDS and SWEDISH FISH confectionery brands, slated to launch in August 2026 across around 2,200 Walmart stores and 1,300 GNC corporate stores in the United States and Canada.

Chief executive Thomas Ryder described the acquisition as "an important step for Applied Nutrition in North America," adding that "the United States remains a major Long-term Growth market." Nutrablend chief executive Jack Sehgal said the buyer's status as a publicly listed company "provides transparency, credibility and trust which will resonate with customers."

Key Financial Numbers

Applied Nutrition's interim results, published on 23 March 2026 and covering the six months to 31 January 2026, illustrate the pace of growth. Revenue rose 56.5% to £74.5m, from £47.6m a year earlier, while Gross Profit climbed to £34.8m, holding the gross Margin broadly flat at 46.7%.

Adjusted EBITDA increased 55.8% to £21.5m, keeping the adjusted EBITDA margin close to 29%. Adjusted profit before tax was £20.9m, up from £13.6m, and Basic Earnings Per Share reached 6.2p, against 3.5p in the prior period. The Balance Sheet strengthened, with net cash of £26.4m at the half-year, more than double the £10.9m reported a year before. No Interim Dividend was declared, and the company has indicated it does not anticipate paying one before its 2027 financial year.

The upgrades have been sequential. A trading update on 9 December 2025 flagged that full-year results were likely to exceed market consensus by around 10%. By February 2026, guidance had been set at roughly £140m of revenue, and by June the company said it expected approximately £148m, excluding any Nutrablend contribution, comfortably ahead of the £140.3m consensus it cited. It expects the group's EBITDA margin to remain in line with consensus expectations of about 28%.

What Is Driving the Business

Two forces are propelling Applied Nutrition. The first is distribution. The group has broadened its reach across UK grocers, discounters and specialist health retailers, and reported that retail orders and resulting customer stock levels ran significantly above expectations in the first half. The second is international expansion, with markets outside the UK now generating the majority of sales.

The Nutrablend acquisition addresses a structural constraint: manufacturing and shipping product into North America from the UK. By owning capacity in Buffalo, the company aims to shorten lead times, accelerate new launches, improve supply-chain resilience and open a route into white-label manufacturing. The Mondelez tie-up, meanwhile, offers a high-profile endorsement and immediate shelf space in two of North America's largest retail channels.

What It Means for Investors

The re-rating has been dramatic. Priced at 140p in its October 2024 IPO — valuing the group at around £350m — the shares traded at about 321.5p on 19 August 2026, giving a Market Capitalisation of roughly £804m across its 250 million shares. The stock reached a 52-week high of 355p on 11 August 2026, against a low of 147p last summer.

Repeated upgrades and a strengthening cash position have clearly rewarded early backers. That said, the shares now trade on a valuation that leaves limited room for disappointment, placing a premium on the company continuing to deliver against its raised expectations.

Risks and Challenges

The most obvious risk is execution. Integrating a US manufacturing operation, standing up a new commercial relationship with Mondelez and scaling North American distribution simultaneously is demanding for a company of Applied Nutrition's size. Management cautioned that Nutrablend is not expected to make a meaningful contribution in the current financial year, projecting at least $30m of revenue at a high single-digit EBITDA margin only from FY27.

Sports nutrition is also intensely competitive and exposed to shifting consumer trends, input-cost Inflation and currency movements, the latter increasingly relevant given the dollar exposure a US plant introduces. The absence of a dividend, at least for now, means the Investment case rests entirely on continued growth.

What Comes Next

Attention turns to the full-year results for the 12 months to 31 July 2026, which on the prior year's timetable would be expected in the autumn. Investors will look for confirmation that revenue landed around the upgraded £148m mark and that margins held. The August launch of the Mondelez-branded ranges in Walmart and GNC will provide an early read on North American demand, while the pace of Nutrablend's integration will shape expectations for FY27.

Conclusion

Applied Nutrition has used its first full year as a public company to build momentum, converting buoyant demand into successive guidance upgrades and backing its North American ambitions with hard manufacturing capacity. The strategy is coherent and the numbers, so far, support it. The challenge now is execution: turning a well-timed acquisition and a marquee Brand Partnership into durable, profitable growth in the world's largest supplements market — and justifying a valuation that has already travelled a long way from its IPO price.